Omeros Corporation Aktie News

Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joining a rally that has room to continue is powerful.

Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglobinuria with a differentiated mechanism, offering potential safety and dosing advantages over existing complement inhibitors. Recent phase 2 data showed significant improvements in hemoglobin and L...

Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to di...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global ex...

Shares of Omeros (OMER 153.90%) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER's press release, this deal grants Novo exclusive global rights to develop and commercialise its MASP-3 inhibitor, zaltenibart (formerly OMS906), across all indications.

Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.